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Abstract
BACE1 is a key enzyme for amyloid-b (Ab) production, and an attractive therapeutic target in Alzheimer’s disease (AD). Here
we report that BACE1 inhibitors have distinct effects on neuronal Ab metabolism, inducing a unique pattern of secreted Ab
peptides, analyzed in cell media from amyloid precursor protein (APP) transfected cells and in cerebrospinal fluid (CSF) from
dogs by immunoprecipitation-mass spectrometry, using several different BACE1 inhibitors. Besides the expected reductions
in Ab1-40 and Ab1-42, treatment also changed the relative levels of several other Ab isoforms. In particular Ab1-34
decreased, while Ab5-40 increased, and these changes were more sensitive to BACE1 inhibition than the changes in Ab1-40
and Ab1-42. The effects on Ab5-40 indicate the presence of a BACE1 independent pathway of APP degradation. The
described CSF Ab pattern may be used as a pharmacodynamic fingerprint to detect biochemical effects of BACE1-therapies
in clinical trials, which might accelerate development of novel therapies.
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Introduction
Alzheimer’s disease (AD) is the most common neurodegener-
ative disease world-wide [1]. Accumulation of toxic amyloid-b
(Ab) peptides is thought to be at the core of AD pathogenesis [2–
4]. Hence, one of the main targets of novel disease-modifying
drugs is to minimize the brain Ab load by targeting the b- and c-
secretases that cleave the amyloid precursor protein (APP) to
generate Ab [5]. b-Secretase has been identified as the membrane-
anchored aspartyl protease b-site APP-cleaving enzyme 1
(BACE1, also called Asp2 and memapsin2) [6–8]. BACE1
inhibitors are recognized as potential candidates for disease-
modifying AD drugs, but their development has been unsatisfac-
tory to date, due to difficulties identifying compounds with desired
effects in the central nervous system (CNS), especially due to
difficulties in achieving blood-brain barrier penetration [5,9].
Markers of biochemical drug effects in vivo - so called theragnostic
or pharmacodynamic biomarkers - could identify effective
compounds and facilitate drug development [10]. Analysis of Ab
isoforms in the cerebrospinal fluid (CSF) is a potentially
informative measure of APP metabolism occurring in the brain.
We tested here the hypothesis that a distinct Ab peptide pattern
can be used to identify effects of BACE1 inhibition in mammals,
by analyses in cell media and in dog CSF. Several Ab isoforms
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exist in vivo, depending on different degradation pathways of APP
[11]. Ab in plaques consists of up to 43 amino acids, with Ab4-42
and Ab1-42 being among the most abundant [12–14]. In contrast,
the Ab pattern in CSF is dominated by Ab1-40 and several C-
terminally truncated isoforms ranging down to Ab1-13, with Ab1-
42 present only in small amounts [15,16]. The membrane-bound
c-secretase complex is directly or indirectly involved in the APP
processing that produces the different C-terminal endings of Ab in
the range Ab1-17 to Ab1-42 [17,18] while BACE1 mediates the
cleavages at both the N-terminal and at Glu11 of Ab to produce
Ab1-X and Ab11-X isoforms [7]. APP may also be cut by a-
secretase enzymes within the Ab domain [19,20], and a- and b-
secretase pathways may converge to produce short Ab peptides,
including Ab1-14, Ab1-15 and Ab1-16 [17,18].
We show here that BACE1 inhibition results in a distinctly
altered CSF Ab pattern, including reduced levels of Ab1-34 and
increased levels of Ab5-40, besides the expected reduced levels of
Ab1-40 and Ab1-42. The Ab5-40/Ab1-34 ratio was highly
elevated in the CSF of treated animals and clearly distinguished
active treatment from placebo. This Ab pattern may be useful as a
specific and sensitive pharmacodynamic fingerprint of BACE1
inhibition to assess in vivo biochemical effects in CNS in
clinical trials of BACE1 inhibitors and thereby accelerate drug
development.
Results
BACE1-inhibition induces a specific Ab peptide pattern in
cell media
To investigate the effects of BACE1-inhibition on neuronally
secreted Ab, human neuroblastoma SH-SY5Y cells stably
expressing human APP695wt were treated with the BACE1
inhibitor b-secretase inhibitor IV. Immunoprecipitation-mass
spectrometry (IP-MS) analysis of the cell media displayed a
distinct shift in the Ab isoform pattern in response to treatment
including an anticipated decrease in the peak intensity of Ab1-40
but increased intensities of Ab5-38 and Ab5-40 (Fig. 1a–b, Fig. 2a).
Relative to other isoforms, treatment clearly increased the levels of
Ab5-40, while the levels of most other isoforms tended to be
reduced (Fig. 2b). These BACE1 induced alterations in the Ab
isoform pattern were supported by immunoassay data showing
decreased concentrations of Ab1-40 and Ab1-42 but no major
effects on AbX-40 and AbX-42 (Fig. 2c–f). The concentrations of
sAPP-b decreased and sAPP-a increased in response to treatment,
further supporting that BACE1 inhibition induces a shift in APP
processing pathways (Fig. 2g–h). The altered Ab peptide pattern
was unique to BACE1 inhibition and was not seen when cells were
treated with a c-secretase inhibitor or a cathepsin B-inhibitor
(Fig. S1).
The effects of BACE1 inhibition are consistent across cell
models and treatments
We evaluated if the effect on secreted Ab peptides was
compound-specific or a general response to BACE1 inhibition.
SH-SY5Y APP695wt cells were treated with another BACE1-
inhibitor, the potent AstraZeneca compound AZ-20 [21]
(IC50 = 8.261.4 nM [SEM], N = 3), which had very similar effects
as b-secretase inhibitor IV on the Ab isoform pattern, including
concentration-dependent increases in the relative levels of Ab5-38
and Ab5-40 (Fig. 1c–d, Fig. 3a, Fig. S2a). We also analyzed the
effects of AZ-20 on SH-SY5Y cells transfected with the Swedish
APP mutation (APP695swe). Again AZ-20 increased the relative
levels of Ab5-38 and Ab5-40 (Fig. 1e–f, Fig. 3b). To examine if the
effects of BACE1 inhibition were restricted to neuronal cells, a
CHO-cell line (7PA2 APP751 with the V717F FAD-mutation) was
treated with AZ-20. These cells released a complex Ab isoform
pattern (Fig. 1g–h), but treatment increased the relative levels of
Ab5-33, Ab5-38, Ab5-40, and Ab5-42 (Fig. 1.g-h, Fig. 3c, Fig. S2c).
To further verify that the effects on Ab secretion were general
across different cell models, we treated HeLa-APPswe cells with b-
secretase inhibitor IV, resulting in increased relative levels of Ab5-
38 and Ab5-40 (Fig. 1i–j, Fig. 3d, Fig. S2d–e). Similar results were
obtained for siRNA against BACE1 in HeLa-APPswe cells
(Fig. 1.k–l, Fig. 3e, Fig. S2e).
Together, these experiments indicated that the general effect of
BACE1 inhibition was to reduce the release of most Ab peptides,
but increase the release of Ab5-38 and Ab5-40.
BACE1 inhibition affects CSF Ab peptides in mammals
We proceeded to verify that the altered neuronal Ab pattern
may be used to identify biochemical effects of BACE1-inhibition in
CNS in mammals, by examining CSF from dogs treated with two
different BACE1 inhibitors (the cyclic sulfoxide hydroxyethyla-
mine NB-B4 and the oxazine derivative NB-C8, obtained from
Novartis [22]). In total, 14 Ab isoforms were reproducibly detected
by IP-MS in all dogs and used for further analysis (Fig. 4a).
Treatment with either of the compounds reduced the absolute
CSF signal of all Ab isoforms except Ab5-40 (Fig. 4b–c). For
relative levels, a reduction was seen for Ab1-34, while Ab5-40
clearly increased (Fig. 4d–e). For NB-C8, multiple time-points
where analyzed and the relative levels of Ab5-40 increased over
time (Fig. 4e). Treatment decreased the absolute, but not the
relative levels of Ab1-40 (Fig. 4b–e).
The CSF Ab peptide pattern as a pharmacodynamic
fingerprint of BACE1 inhibition
To investigate if a combination of Ab peptides could be used to
increase the separation between groups, we performed a
multivariate analysis including all identified Ab isoforms, and
compared dogs on active treatment and placebo for each
investigated drug. It was possible to construct a model for NB-
C8 versus placebo that achieved a complete separation between
groups that increased with time after drug administration (Fig. 5a).
The time dependency was still present when data from the NB-B4
treated dogs were entered into the model. The most important Ab
peptides in the model were Ab5-40 with increased relative
intensity and Ab1-34 with decreased relative intensity after
treatment (Fig. 5b). The CSF Ab5-40/Ab1-34 ratio was a more
sensitive measurement of BACE1 inhibition than the expected
pharmacodynamic markers CSF Ab1-40 and CSF Ab1-42
(Fig. 5c–d). It should be noted that this study was carried out on
post-mortem CSF. To verify that the changed Ab pattern was not
a result of unspecific degradation in post-mortem CSF or cell
media, and to further validate the generalizability of the CSF
biomarker fingerprint across different BACE1-inhibitors, we
evaluated CSF Ab5-40 and Ab1-34 in an independent group of
live dogs treated with another BACE1-inhibitor (BACE1-inhibitor
S, obtained by Janssen). The CSF Ab5-40/Ab1-34 ratio increased
in dogs on active treatment versus dogs treated with placebo
(Fig. 5e). For the highest treatment dose we also evaluated
temporal effects, and noted maximal effects on the CSF Ab5-40/
Ab1-34 ratio at 25 h after treatment and a regression towards
baseline at 49 h in this single-dose study (Fig. 5f).
Discussion
BACE1 is one of the prime targets for disease-modifying AD
therapy [9,23–27], and BACE1 inhibition has also been suggested
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as a therapeutic approach for nerve injury [28]. Here we show that
BACE1-inhibition induces a specific CSF Ab pattern, primarily
characterized by reduced relative levels of Ab1-34 and increased
relative levels of Ab5-40. In addition to measuring single Ab
isoforms, including Ab1-40 and Ab1-42 by enzyme-linked
immunosorbent assays (ELISAs) or other immunoassays, the
CSF Ab pattern (including the Ab5-40/Ab1-34 ratio) may give
complementary information on the change in Ab and APP
metabolism. We propose that these biomarkers are a useful
pharmacodynamic fingerprint of BACE1 inhibition to detect in
vivo drug effects in the CNS, which may accelerate drug
development, by verifying compound efficiency in the target
organ, identifying treatment responders and facilitating optimal
dosage. We verified the generalizability of the biomarker pattern
across multiple cell types and in dog CSF, using several different
BACE1-inhibiting regimes. Albeit with some differences for
individual models, the BACE1 inhibition biomarker panel was
generally consistent, especially regarding the increase in Ab5-40
after BACE1 inhibition, which was a ubiquitous finding. The
decrease in Ab1-34 was prominent in CSF but not in all cell
models. Humans and dogs have identical Ab sequences and very
similar CSF Ab patterns. c-secretase inhibition induces a unique
CSF Ab peptide pattern in both species [29,30], supporting dog
models for studies on CSF pharmacodynamic biomarkers.
As expected, we also found decreased levels of Ab1-40 and Ab1-
42, in accordance with previous observations in a rhesus monkey
model [31] and in humans [32]. Yet, CSF Ab1-42 may not be an
optimal biomarker in AD trials. For example, c-secretase
inhibition in AD patients lack effects on CSF Ab1-40 and Ab1-
42 [33], which might suggest that the tolerated doses in humans
were too low to produce the anticipated reductions of CSF Ab1-40
and Ab1-42. However, c-secretase inhibition reduces the levels of
CSF Ab1-34 and increases the levels of CSF Ab1-15 and Ab1-16
even at doses not effecting Ab1-40 and Ab1-42, indicating that
other isoforms may be more sensitive pharmacodynamic markers
than Ab1-40 and Ab1-42 [18,29,30,34]. Ab1-34 is an intriguing
peptide, since both the cleavages at position 1 and 34 depend on
BACE1, and the cleavage at position 34 also depends on c-
secretase [35,36]. Together, these studies illustrate the complexity
of therapy-altered APP catabolomics (Fig. 6).
Much is known about in vitro properties of BACE1 inhibitors
[37], but there is a need for characterization of their effects in vivo.
Our data fully support BACE1 as the main b-secretase for full
length Ab peptides [38–40], but also point to an alternative APP
processing pathway, producing Ab5-X peptides. The increased
levels of Ab5-X in cell media and CSF after BACE1 inhibition is
consistent with previous reports on Ab5-40 formation being stable
despite BACE1 inhibition [17,41], and might be linked to caspase
activity [41]. It is not clear to what extent BACE1 and the
unidentified enzyme cutting at position 5 in the Ab sequence
compete for the same APP substrates. Further studies on APP
compartmentalization and the molecular characteristics of the
Ab5-X isoforms, including their resistance to degradation, are
necessary to clarify how this novel pathway relates to the
established APP processing pathways. It remains to be determined
if the concentration of Ab5-X isoforms varies with cerebral
BACE1 activity, which may be increased in AD [27,42–47]. Small
amounts of Ab5-X peptides are present in AD brains [13,48,49]
(and less in control brains [14]), in vascular lesions with amyloid
angiopathy and in neurofibrillary tangles [41]. Studies of the
biological functions of Ab5-X may give clues on the role of this
novel pathway of APP degradation, and reveal if its regulation
participate in AD pathogenesis.
In conclusion, CSF Ab peptide levels seem to be direct
measurements of the effects of BACE1 inhibition on APP-
processing in the CNS, and the strongest effects are seen for
Ab5-40 and Ab1-34. The CSF Ab5-40/Ab1-34 ratio is a sensitive
acute pharmacodynamic biomarker for BACE1 inhibition. Studies
on the APP processing pathway generating Ab5-40, and
identification of the enzyme(s) responsible for its production,
may aid to the current understanding on how APP and Ab
metabolism exerts its putative damaging effects in AD.
Materials and Methods
Ethics Statement
This study was carried out with ethical approvals given by the
Basel City Cantonal Veterinary Authority (Novartis study) and the
Ethical Committee on Laboratory Animal Testing (ECD, Janssen
Beerse, Janssen study, Permit number: 2009-252-SD).
Cell experiments
SH-SY5Y cells [50] obtained from the European Collection of
Cell Cultures (ECACC 94030304) (stably expressing human
APP695wt or APPswe), 7PA2 cells obtained from the Laboratory
of Dennis J. Selkoe at Harvard Medical School, Boston (APP751
with the V717F mutation [51,52]), and HeLa cells [53] (APPswe),
were maintained in Dulbecco’s modified Eagle’s medium F-12
(Invitrogen) supplemented with 10% fetal bovine serum, L-
glutamine and antibiotics. SH-SY5Y cells were treated with the
BACE1-inhibitor b-secretase inhibitor IV (Calbiochem, Merck,
compound 3 in [54]) or DMSO and incubated for 20 h. SH-SY5Y
cells and 7PA2 cells were treated with the BACE1 inhibitor AZ-20
[21] or DMSO and incubated for 16 h. HeLa cells were treated
with b-secretase inhibitor IV or DMSO and incubated for 4 h.
Two Stealth siRNAs against BACE1 (Invitrogen) were used for
reverse transfection in HeLa-APPswe cells. A scrambled siRNA
sequence containing medium GC content was used as a control.
Sixty-nine h after reverse transfection using Oligofectamine, the
medium was replenished with medium containing 10% Alamar
Blue, and incubated for 3 h. All cell medium was stored at280uC.
Animal experiments
The BACE1 inhibitors NB-B4 and NB-C8 (obtained from
Novartis [22]) were used in experiments with 26 beagle dogs, aged
2–11 years. Animals were pseudorandomly allocated to groups to
control for the effects of age (NB-B4 and NB-C8) and gender (NB-
C8 only). A vehicle group was included. Fasting animals were
dosed orally with 2 mL/kg (NB-B4) or 1.5 mL/kg (NB-C8) (in
0.5% methylcellulose/0.1% Tween80) and sacrificed with intra-
venous pentobarbital overdose (at least 50 mg/kg, approximately
Figure 1. Mass spectra of Ab isoform patterns in all cell models investigated. SH-SY5Y APP695wt cells treated with DMSO (Panels a and c),
5 mM b-secretase inhibitor IV (Panel b) or 10 mM AZ-20 (Panel d). SH-SY5Y APP695swe cells treated with DMSO (Panel e) or 10 mM AZ-20 (Panel f).
7PA2 APP751 V717F cells treated with DMSO (Panel g) or 10 mM AZ-20 (Panel h). HeLa APPswe cells treated with DMSO (Panel i) or 10 mM b-secretase
inhibitor IV (Panel j). HeLa APPswe scrambled siRNA transfected control cells (Panel k) and cells transfected with single oligo siRNAs against BACE1
(Panel l). The mass-to-charge ratio (m/z) of the [M+H]+ ion of Ab5-38 is very close to that of Ab1-33, causing the peaks to partially overlap and making
quantification difficult, wherefore both isoforms were excluded from quantitative analysis. Those peptides are instead presented in these mass
spectra as expanded inserts (except for panels g-h where they are clearly visible).
doi:10.1371/journal.pone.0031084.g001
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0.5 mL/kg), at 6 h (NB-B4), 3 h (NB-C8) or 16 h (NB-C8). CSF
samples were taken from the cisterna magna, aliquoted and stored
at 280uC.
The BACE1-inhibitor S (obtained from Janssen) was used in an
experiment with 16 beagle dogs, aged 1–4 years. Two male and
two female dogs were included per group. A vehicle group was
Figure 3. Cell medium Ab isoform patterns. SH-SY5Y APP695wt cells treated with AZ-20 (Panel a). SHSY-5Y APP695swe cells treated with AZ-20
(Panel b). 7PA2 APP751 V717F cells treated with AZ-20 (Panel c). HeLa-APPswe cells treated with b-secretase inhibitor IV (Panel d). HeLa-APPswe mock
and scrambled siRNA-transfected control cells, and cells transfected with single oligo siRNA or pooled siRNA against BACE1 (Panels e). N = 1 for each
concentration and treatment.
doi:10.1371/journal.pone.0031084.g003
Figure 2. SH-SY5Y APP695wt cells treated with b-secretase inhibitor IV. Peak intensities of all Ab isoforms detected (Panel a). Normalized
(against the sum for all the Ab peaks in the spectrum) levels in relation to controls (DMSO) (Panel b). Immunoassay measurements of Ab1-40 and
AbX-40 (Panels c–e), Ab1-42 and AbX-42 (Panels f–g), sAPP-a and sAPP-b (Panels h–i). Note that the X-40/42 groups may consist of a large variety of
species not detected with the MALDI-TOF-MS method utilized in this work, including such spanning the b-secretase site. N = 3 for each concentration.
Data are means and error bars are SD in panels a–b.
doi:10.1371/journal.pone.0031084.g002
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included. Fasting animals were dosed orally with 1 mL/kg
BACE1-inhibitor S at doses 0.31, 1.25 and 5 mg/kg (in 20%
hydroxypropyl-b-cyclodextrin and tween). CSF samples were
taken from the cisterna magna under short general anesthesia
(0.2 mL medetomidine and 2 mL propofol), aliquoted and stored
at 280uC.
Immunoassays
Cell medium was analyzed for sAPP-a and sAPP-b using the
MSD sAPPa/sAPPb Multiplex Assay [27] (Meso Scale Discovery,
Gaithersburg, MD, USA) and for Ab1-40/42 and AbX-40/42
using the Luminex xMAP assay INNO-BIA Ab forms [55]
(Innogenetics, Gent, Belgium). Cells treated with AZ-20 were
Figure 4. CSF Ab isoform patterns. Dogs treated with vehicle (N= 15), NB-C8 (N= 3 at 3 hours, N = 3 at 16 hours) and NB-B4 (N= 5 at 6 hours).
Mass spectra of the Ab isoform pattern from dogs treated with placebo (Panel a, upper panel) or NB-C8 16 hours post treatment (Panel a, lower
panel). The expanded sections show Ab1-33, Ab1-34, Ab5-38 and Ab5-40. Ab1-33 and Ab5-38 were excluded from quantitative analysis since their
peaks partially overlap, making quantification difficult. Absolute (Panels b–c) and normalized (Panels d–e) mass spectral peak intensities of all
detected Ab isoforms. Statistical significances were tested for normalized peak intensities comparing different treatments. For NB-B4, significant
differences were seen for Ab5-40 (P = 0.001), Ab1-34 (P = 0.001) and Ab11-40 (P = 0.002). For NB-C8, significant differences were seen between vehicle
and treatment at 16 h for Ab5-40 (P = 0.01) and Ab1-34 (P = 0.05). Data are means; error bars are SD.
doi:10.1371/journal.pone.0031084.g004
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Figure 5. Multivariate analysis and CSF Ab5-40/Ab1-34. Multivariate discriminant analysis of the CSF Ab pattern for treatment compared with
placebo in dogs treated with vehicle (N = 15), NB-C8 (N= 3 at 3 h, N= 3 at 16 h) and NB-B4 (N= 5 at 6 h) (Panels a–b). Score vector results including
medians (Panel a). Samples were taken 3 h (open triangles), 6 h (filled squares) or 16 h (filled triangles) after treatment. The groups denoted by ‘‘T’’
were used for constructing the multivariate model while ‘‘P’’ represents the prediction set used for testing the stability of the model. In the
construction of the model, all dogs treated with NB-C8 were regarded equal, independent of time after drug administration. Relative contributions of
different isoforms to group separations, with increased or decreased relative levels in the treated groups, are shown by white or grey bars,
respectively (Panel b). Change of the CSF Ab5-40/Ab1-34 ratio in relation to change of CSF Ab1-40 (Panel c) and CSF Ab1-42 (Panel d). The Ab5-40/
Ab1-34 ratio was a more sensitive biomarker than Ab1-40 and Ab1-42 in terms of change from baseline (the dotted lines indicate predicted
correlations for biomarkers affected equally by treatment). Dogs treated with vehicle (N = 4) and BACE1 inhibitor S obtained from Janssen (N= 4 for
each dosage) (Panel e). The CSF Ab5-40/Ab1-34 ratio completely separated dogs on active treatment versus placebo (P = 0.005 using the Mann-
Whitney U test for comparison of all animals on active treatment versus placebo). Time-dependent dynamics of the ratio in high dose treatment
(Panel f).
doi:10.1371/journal.pone.0031084.g005
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assayed for Ab40 using ELISA (Invitrogen) to determine the half
maximal inhibitory concentration (IC50).
Immunoprecipitation and mass spectrometry
Ab peptides were immunoprecipitated using Ab-specific
antibodies coupled to magnetic beads [15]. Briefly, 4 mg of the
anti-Ab antibodies 6E10 and 4G8 (Signet Laboratories, Dedham,
MA, USA) was separately added to 50 mL each of magnetic
Dynabeads M-280 Sheep Anti-Mouse IgG (Invitrogen, Carlsbad,
CA, USA). The 6E10 and 4G8 antibody-coated beads were mixed
and added to the cell media or CSF to which 0.025% Tween20 in
phosphate-buffered saline (pH 7.4) had been added. After
washing, using the KingFisher magnetic particle processor, the
Ab isoforms were eluted using 100 mL 0.5% FA. Mass
spectrometry measurements were performed using a Bruker
Daltonics UltraFleXtreme matrix-assisted-laser-desorption/ioniza-
tion time-of-flight/time-of-flight (MALDI TOF/TOF) instrument
or a Bruker Daltonics AutoFlex MALDI TOF (Bruker Daltonics,
Bremen, Germany). All samples were analyzed in duplicate. An in-
house MATLAB (Mathworks Inc. Natick, MA, USA) program
was used for relative quantification of the Ab isoforms. For each
peak the sum of the heights for the three highest isotopes were
averaged followed by normalization against the sum for all the Ab
peaks in the spectrum. When a ratio between two Ab isoforms was
calculated the normalization step was omitted. It should be noted
that a relative quantification cannot be interpreted as a direct
reflection of an absolute or relative abundance of an isoform since
the ionization efficiency might be different for different isoforms
and since different isoforms are more hydrophobic than others.
Liquid chromatography and tandem mass spectrometry
To confirm isoform identities, the immunoprecipitates were also
analyzed by liquid chromatography (LC) combined with high
resolution tandem mass spectrometry (MS-MS) [15], on an Ettan
MDLC nanoflow chromatographic system (GE Healthcare) using
HotSep Kromasil C4 columns (G&T Septech) coupled to a
Thermo LTQ-FT Ultra electrospray ionization hybrid linear
quadrupole ion trap/Fourier transform ion cyclotron resonance
(ESI-LQIT/FTICR) mass spectrometer (Thermo Fisher Scientif-
ic). All spectra were acquired in FTICR mode and collision
induced dissociation was used to obtain fragment ion data.
Statistical analysis
In the dog experiments, we compared each mass spectrometric
peak between different treatment groups using the non-parametric
Mann-Whitney U test (corrected for multiple comparisons using
Bonferroni correction) for pair-wise comparisons and the Kruskal-
Wallis test (followed by Dunn’s post hoc test) for multiple groups.
Multivariate analysis was performed using the orthogonal
projections to latent structures discriminant analysis (OPLS-DA)
algorithm [56,57] (SIMCA-P+, v.12, Umetrics, Umea˚, Sweden),
which finds the direction in the multivariate space spanned by the
analytes which best separates the predefined groups. The studies
on dogs treated with NB-B4 and NB-C8 were conducted
separately, with individual vehicle groups for each, but no
differences in biomarker levels were found between the two
vehicle groups, wherefore all vehicle treated animals were used as
one control group in this analysis.
Supporting Information
Figure S1 Mass spectra displaying the Ab isoform
pattern in media from SH-SY5Y APP695wt cells treated
with DMSO (Panel a), a cathepsin-B inhibitor (Z-FA-
FMK 5 mM) (Panel b), and c-secretase inhibitor (DAPT
1 mM) (Panel C).
(TIF)
Figure S2 Absolute spectral peak intensities of all Ab
isoforms detected in cell media. SH-SY5Y APP695wt cells
treated with AZ-20 (Panel a). SH-SY5Y APP695swe cells treated
with AZ-20 (Panel b). 7PA2 APP751 V717F cells treated with AZ-
20 (Panel c). HeLA-APPswe cells treated with b-secretase inhibitor
IV (Panel d). HeLA-APPswe mock and siMEDGC transfected
control cells, and cells transfected with single oligo SiRNA or
pooled SiRNA (Panel e).
(TIF)
Figure 6. Summary of processing pathways. The main pathways of Ab peptide release and how these are affected by BACE1 inhibition (arrows
indicate absolute and/or relative changes). The APP box shows major APP cleaving secretases with selected cleavage sites that depend on them.
doi:10.1371/journal.pone.0031084.g006
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